Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Quince Therapeutics, Inc. (CRTX)
|
Add to portfolio |
|
|
|
| Price: |
$35.68
| | Metrics |
| OS: |
36.4
|
M
| |
|
|
| Market cap: |
$1.3
|
B
| |
|
|
|
Net cash:
|
$85.5
|
M
| |
$2.35
|
per share
|
|
EV:
|
$1.21
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($51.0)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 9.1 |
| Revenue growth | | | | | -100.0% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10.4 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.3 |
| Gross margin | | | | | | -14.0% |
| Research and development | 25.2 | 60.8 | 61.3 | 30.2 | 10.1 | |
| General and administrative | 26.0 | 29.5 | 17.6 | 9.0 | 2.0 | 1.3 |
| EBIT | -51.2 | -90.3 | -78.9 | -39.2 | -12.1 | -10.4 |
| EBIT margin | | | | | | -114.0% |
| Pre-tax income | -51.9 | -89.9 | -76.8 | -37.0 | -12.5 | -12.2 |
| Income taxes | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -51.9 | 0.0 | -76.8 | -37.0 | -12.5 | -12.2 |
| Net margin | | | | | | -134.5% |
| |
| Diluted EPS | ($1.55) | $0.00 | ($2.63) | ($1.94) | ($3.71) | ($3.70) |
| Shares outstanding (diluted) | 33.5 | 29.7 | 29.2 | 19.0 | 3.4 | 3.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|